Objectives-This study assessed the diagnostic performance of transabdominal oral contrast-enhanced ultrasound (US) imaging for preoperative tumor staging of advanced gastric carcinoma by comparing it with transverse contrast-enhanced computed tomography (CT).
for the survival time and rate. 3 Patients at an early stage are often asymptomatic; however, most patients are already at an advanced stage at the time of diagnosis. Surgery and neoadjuvant therapy are the main therapeutic strategies for advanced gastric cancer. 4 Accurate preoperative staging is important for making decisions in individualized therapeutic regimens. Therefore, the challenge for the clinician lies in accurate preoperative staging and applying treatment appropriate to the stage.
Endoscopic ultrasound imaging is currently the most effective nonsurgical method for evaluating the primary tumor because of its ability to differentiate the 5 layers of the gastric wall and diagnostic accuracy of 78% to 92% for all tumor stages. [3] [4] [5] [6] [7] Compared with other imaging modalities, endoscopic US imaging has higher accuracy for stage T1 cancer. [5] [6] [7] However, an endoscopic US examination is an invasive technique with a risk of perforation, and discomfort limits its application in the aged population. 8, 9 Computed tomography (CT) is an accurate and effective tool for preoperative staging of gastric cancer and allows detection of lymph nodes and distant metastases. [10] [11] [12] However, its high costs impede the use of CT in rural areas.
Transcutaneous US imaging has not been considered an appropriate method for routinely assessing stomach disorders and cancer because the accuracy and reliability of hydrosonography are low, and there have been contrast agent-related side effects (such as nausea, vomiting, and diarrhea). [13] [14] [15] [16] At this time, there is a new type of cereal-based oral contrast agent that can produce nearly homogeneous hyperechogenicity in the gastric lumen and can remain for enough time for a detailed examination. [17] [18] [19] [20] [21] However, there is little research on the preoperative tumor staging of gastric cancer using this oral contrast agent. We hypothesized that cereal-based oral contrast-enhanced transcutaneous US can enable the preoperative tumor staging of advanced gastric cancer with accuracies comparable to those achieved with transverse contrast-enhanced CT. This study aimed to verify that hypothesis by comparing the diagnostic value of transabdominal oral contrast-enhanced US with transverse contrast-enhanced CT for preoperative tumor staging of gastric carcinoma.
Materials and Methods

Patients
This study was approved by the Institutional Review Board of Chongqing Medical University, and patient informed consent was waived, as this work was a retrospective study. Between July 2011 and June 2016 (mainly 2011-2012), 60 consecutive patients with a diagnosis of gastric cancer in our hospital were enrolled in this study. The inclusion criteria were as follows: (1) patients were examined by both transabdominal oral contrast-enhanced US and transverse contrast-enhanced CT; (2) patients underwent laparoscopy, radical surgery, or palliative surgery (only for patients with perforation, uncontrolled bleeding, or serious obstruction) and had been pathologically staged; (3) patients had a body mass index of less than 25 kg/m 2 . The exclusion criteria were as follows: (1) the patient refused surgery or laparoscopy; (2) the patient chose to get treated elsewhere; (3) the pathologic results were not gastric cancer; (4) the patient had a body mass index of 25 kg/m 2 or greater. Finally, 42 patients were enrolled. Seventeen patients were excluded, as they had either refused further examination or had been transferred to other hospitals. One was excluded because of pathologically confirmed non-Hodgkin lymphoma.
Transabdominal US Imaging
Before the transabdominal contrast-enhanced US examination, patients were asked to drink about 400 mL of a cereal-based oral contrast agent (commercially available Tianxia brand, 50 g/pack, with grain as the main ingredient; East Asia Institute of Gastrointestinal Ultrasound, Huzhou, China) after 8 h of fasting. Transabdominal US examinations were performed by 2 radiologists, with greater than 5 years of abdominal imaging experience who specialized in gastrointestinal US, before intake of the oral contrast agent and thereafter.
Ultrasound images in all locations from the distal esophagus to the antrum and duodenal bulb were obtained with a convex array transducer with a frequency of 2.5 to 5 MHz (HI VISION Preirus; Hitachi Medical Corporation, Tokyo Japan). A high-frequency transducer of 7 MHz was applied to detect some lesions located in the greater curvature or gastric antrum.
With the patient in the supine position, the cardia and fundus, which were located behind the left liver, were imaged by slightly angling the transducer toward the left shoulder. When the contrast agent entered the stomach, the conjunction of the cardia and gastric fundus visualized as a trumpet-like appearance. The gastric body and antrum were imaged in the right lateral position, with continuous scanning in both transverse and longitudinal sections and angling of the transducer toward the left subcostal area. [13] [14] [15] [16] [17] [18] [19] [20] [21] Gastric emptying (contraction and relaxation) was observed in real time.
Computed Tomographic Protocol
After the transabdominal oral contrast-enhanced US examination, CT scans were performed on another day within 1 week with a 64-detector row CT scanner (Light Speed; GE Healthcare, Milwaukee, WI). The following scan parameters were used: 120 kV, 360 mA, 36-cm field of vision, and 5-mm slice thickness and interval. Before the CT examination, each patient ingested 600 to 1200 mL of water after 6 hours of fasting. Computed tomographic images were obtained with patients in the supine position. The scanning ranged from the diaphragm edge to the anterior superior iliac spine. After a noncontrast scan, 90 mL of the intravenous contrast agent Omnipaque (Shanghai GE Healthcare, Shanghai, China) was administrated via an antecubital vein at a rate of 3 mL/s, followed by 30 mL of 0.9% saline. Images were acquired in the arterial phase (30 seconds) and the venous phase (70 seconds). In addition, no hypnotic drug was used for US or CT examinations.
Image Storage and Analysis
Both contrast-enhanced US and contrast-enhanced CT images were analyzed in a blinded manner by 2 independent radiologists with greater than 5 years of abdominal (especially gastrointestinal) imaging experience within a week, respectively. For contrast-enhanced US, videos were also stored and analyzed. The intraobserver reliability was evaluated 2 weeks later after the first analysis. 19 Impressions of preoperative tumor staging with either transabdominal oral contrast-enhanced US or transverse contrast-enhanced CT were sent to the surgical department with the written report without sharing of any information. The stage of gastric cancer in the 42 cases was confirmed by postoperative pathologic findings and compared with the preoperative tumor staging data by contrast-enhanced US and contrast-enhanced CT.
Pathologic, Contrast-Enhanced CT, and Transabdominal Contrast-Enhanced US Criteria for Tumor Staging of Gastric Cancer The pathologic staging of gastric cancer was determined in accordance with the International Union Against Cancer TNM classification, seventh edition. 22 The pathologic criteria for tumor staging of gastric cancer are as follows: Tis, carcinoma in situ, in which the intraepithelial tumor does not invade into the lamina propria; T1, the tumor invades the lamina propria, muscularis mucosae, or submucosa; T2, the tumor invades the muscularis propria; T3, the tumor penetrates subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures; and T4, the tumor invades the serosa (visceral peritoneum) or adjacent structures.
The contrast-enhanced CT tumor staging of gastric cancer was determined according to the following criteria 23, 24 : T0, no evidence of alteration of the gastric wall with a normal fat plane; T1, focal thickening of the inner layer can be found, which is almost well enhanced and has a visible low-attenuation strip of the outer layer of the gastric wall and a clear fat plane around the tumor; T2, focal or diffuse thickening of the gastric wall with transmural involvement, which is almost well enhanced and has a smooth outer-wall border and a clear fat plane around the tumor; T3, a transmural tumor with an irregular or nodular outer border, perigastric fat infiltration, or both; and T4, obliteration of the fat plane between the gastric tumor and adjacent organs or invasion of adjacent organs.
The transabdominal oral contrast-enhanced US tumor staging criteria were as follows: T0, no evidence of a primary tumor; T1, the tumor invades the mucosa and submucosa; T2, the tumor invades the muscle, and the hyperechoic strip of the serosa is smooth and continuous with uniform thickness; T3, the tumor penetrates into the serosa with an irregular hypoechoic outline; and T4, the tumor projects into the perigastric fat, with or without invasion of adjacent organs. 25 Statistical Analysis SAS version 8.0 software (SAS Institute Inc, Cary, NC) was used. Data were expressed as numbers and percentages. The accuracy, sensitivity, and specificity of transabdominal oral contrast-enhanced US and transverse contrast-enhanced CT for preoperative tumor staging of gastric cancer were determined by using the pathologic findings as the reference standard. The overall accuracy of tumor staging was compared. The McNemar test (Fisher exact test) was used, and P < .05 was considered to indicate a statistically significant difference.
Results
Pathologic Tumor Staging of Gastric Cancer
The pathologic type was adenocarcinoma in all 42 cases, including 8 cases of signet ring cell carcinoma. Among the 42 cases, 25 cases of gastric cancer were poorly differentiated; 12 cases were moderately differentiated; 2 cases were between poorly and moderately differentiated; 2 cases were undifferentiated; and 1 case was well differentiated. Four cases were identified as stage T2; 13 cases were stage T3; 25 cases were stage T4; and there was no stage T1 tumor ( Table 1) .
Detection of Primary Tumors and Tumor Staging by Imaging
For transabdominal oral contrast-enhanced US, the detection rate of advanced gastric cancer in this study was 100%. With regard to the characteristic US findings of gastric cancer, hypoechoic irregular thickening of the gastric wall was shown in all cases. Figure 1A shows the thickened anterior wall of the cardia. Figure 2A shows diffuse thickness of the gastric antrum. Figure 3A shows the thickened wall of the gastric body. The thickness of the gastric wall depended on the tumor infiltration. In 5 of the 42 cases, hypoechoic lumps protruding into the gastric lumen were observed, and the lumps usually occurred together with the thickened wall ( Figure 1B) . Irregular ulcers were very common in most of the cases. Some ulcers were deep (Figure 3, A and B) ; some ulcers were small and shallow ( Figure 4A) ; and some ulcers were wide (Figure 2A) .
On transverse contrast-enhanced CT, a thickened gastric wall with heterogeneous enhancement was shown (Figures 1, C and D, 2B, 3C, and 4B) . The detection rate of advanced gastric cancer in this study was 100% for transverse contrast-enhanced CT, and the locations of the primary tumors are listed in Table 1 .
The overall diagnostic accuracies of tumor staging with transabdominal oral contrast-enhanced US and transverse contrast-enhanced CT were 86% (36 of 42) and 83% (35 of 42), respectively (P > .999). No significant difference was noted in the overall diagnostic rate of tumor staging between contrast-enhanced US and contrast-enhanced CT. For contrast-enhanced US, 3 cases of T2 tumors were overstaged as T3; 1 T3 tumor was overstaged as T4; and 2 T3 tumors were understaged as T2 ( Figure 5 ). For contrast-enhanced CT, 2 cases of T2 gastric cancer were overstaged as T3; 4 T3 tumors were overstaged as T4; and 1 T3 tumor was understaged as T2 (Table 2) .
Side Effects Related to the Contrast Agent
No alimentary symptoms or allergic reactions related to the contrast agent were observed.
Discussion
The layers of the gastric wall can be differentiated transabdominally with oral contrast agents inside the gastric lumen. [16] [17] [18] [19] [20] [21] In this retrospective analysis, the overall accuracy of tumor staging using transabdominal oral contrast-enhanced US (86% [36 of 42]) was comparable with that for contrast-enhanced CT (83% [35 of 42]). There was no significant difference in overall accuracy between transabdominal oral contrast-enhanced US and transverse contrast-enhanced CT.
The reported accuracy of transcutaneous US with oral contrast media (including water) for staging gastric cancer has ranged from 46 to 78%. [14] [15] [16] [17] [18] [19] [20] [21] From our results, the overall accuracy of tumor staging using transabdominal oral contrast-enhanced US was 86%, and for T2, T3, T4, the rates were 88%, 86%, 98%, respectively, which were higher than the reported accuracy rates of 55.6% for T1, 75.0% for T2, 87.3% for T3, and 71.1% for T4 using the hydro technique. 14 Mural gas and gastric mucus adherence to the gastric wall would be increased when the stomach is filled with water, which may influence observations of the gastric wall. 18 Contrast agents not only provide stomach distension and remove air in the gastric lumen but also produce a homogeneous hyperechoic volume in the gastrointestinal lumen, thus providing a relatively stronger background to the gastrointestinal wall and hypoechoic tumors than water from our experience and that of other researchers. [17] [18] [19] Moreover, they can remain longer in the gastric lumen than water, thus offering enough time for the examination. [17] [18] [19] [20] [21] The accuracy of tumor staging of gastric cancer with CT has a wide range of 43% to 89%. [8] [9] [10] [11] [12] 26 The distinct variability of the accuracy is related to the advances in CT technology and the varied numbers of patients at different tumor stages in different studies. 26 In general, there was lower agreement in tumor staging of gastric Figure 1 . A case of cancer located in the gastric cardia and body in a 62-year-old man. It was confirmed as stage T4 gastric cancer pathologically and staged as T4 by both transabdominal oral contrast-enhanced US and contrast-enhanced CT. A, A contrast-enhanced US image showed thickening of the inferior segment of the cardia wall (long arrows), with 2 enlarged lymph nodes in the surrounding tissue (short arrows). B, A contrast-enhanced US image showed the hypoechoic lesion extending to the fundus and projecting into the gastric lumen (arrows). C, An axial contrast-enhanced CT image showed thickening of the inferior segment of the esophagus and cardia wall (long arrows) with 2 lymph nodes in the surrounding tissue (short arrow). D, The irregularly thickened and enhanced gastric wall projected into the lumen, and the tumor penetrated into the serosal outer connective tissue.The hepatogastric space was almost missing (arrows).
cancer at a relatively early stage than at a late stage. 27 Some other studies on this topic reported consistently lower accuracy rates of oral contrast-enhanced US regarding tumor staging. For example, Yu et al, 17 Liu et al, 18 and Li et al 19 reported overall accuracy of oral contrast-enhanced US of 75% to 77%. In this study, contrast-enhanced CT had accuracy of 100% for staging T4 tumors and 83% for staging all of the tumors, which were much higher than in previous reports. First, the criteria for tumor staging were different. Liu et al 18 and Li et al 19 used the sixth edition of the American Joint
Committee on Cancer criteria as the tumor staging standard. Some T2 cases (T2b, tumor invades subserosal tissue, according to these criteria) are classified as T3 according to seventh edition, and some T3 cases (tumor perforates serosa; tissue, according to sixth edition) are staged as T4a according to the seventh edition. Second, the number of early-stage cases affects the overall accuracy. With more early-stage cases included, lower overall accuracy for tumor staging would be shown. For example, in the report by Yu et al, 17 5 T1 cases were included, which lowered the overall accuracy. A gastric antrum ulcer measuring 2 3 3 cm was confirmed as stage T4 gastric cancer pathologically and staged as T4 by transabdominal oral contrast-enhanced US and contrast-enhanced CT in a 52-year-old man. A, A contrast-enhanced US image showed the contour of the gastric lesion in the gastric antrum and body (between two arrowheads). B, A contrast-enhanced US image showed thickening of the gastric wall (white arrowheads) with a deep ulcer containing hyperechoic contrast agent in the gastric antrum (black arrowhead). The border between stomach and pancreas was not clear. C, A transverse CT image showed irregular and lightly enhanced thickening of the gastric wall (long arrows) extending from the gastric antrum to the body. A deep ulcer in the gastric antrum was seen, and the hepatogastric and hepatopancreatic spaces were invaded with 3 enlarged lymph nodes in this region (short arrows). Figure 4 . A case of 56-year-old woman who had abdominal pain and a tarry stool for about 19 days, which was confirmed as stage T3 gastric cancer pathologically and staged as T3 by both transabdominal oral contrast-enhanced US and contrast-enhanced CT. A, A shallow ulcer was found in the middle of the mucosal side (arrow).The thickened gastric wall lightly penetrated into the fat tissue from the serosal side (arrowheads). B, An axial contrast-enhanced CT image showed thickened gastric wall enhancement (long arrows), and the lesion penetrated into the subserosal connective tissue, but the space between the lesion and the adjacent liver was clear (short arrows). T2  1  2  0  88  25  95  T3  3  10  0  86  77  90  T4  0  1  25  98  100  94  Contrast-enhanced CT  T2  2  1  0  93  50  97  T3  2  8  0  83  62  93  T4  0  4  25  90  100  76 a Depth of tumor penetration into the gastric wall. Figure 5 . A 51-year-old woman had a misdiagnosis of stage T2 cancer preoperatively by images and intraoperatively, which was postoperatively diagnosed as stage T3. A, A small ulcer was found in the middle of the mucosal side (arrowhead). The thickened gastric wall was irregular on the serosal side but was neglected preoperatively (arrow). B, A small hypoechoic spot (arrow) projected minimally into the serosal hyperechoic zone when reviewed postoperatively.
Considering transabdominal oral contrast-enhanced US and contrast-enhanced CT together for tumor staging of gastric cancer, 4 cases were overstaged, and 2 cases were under-staged. Inflammation due to ulcerations in the tumor and peritumoral tissues has a similar hypoechoic appearance as a tumor, potentially leading to overstaging by US compared with pathologic finidngs. 28 Understaging has been considered to be caused by microtumor invasion beyond the US equipment's resolution or sonographer's scanning technique. 28 One T3 tumor confirmed by pathologic analysis and contrast-enhanced CT was understaged as T2 on contrast-enhanced US, and further evidence for a T3 diagnosis was found on reviewing the video and images. Therefore, a "second look" at the videos and images before presenting the final report is also very important for the reporter.
This study showed similar diagnostic accuracy of transabdominal oral contrast-enhanced US and transverse contrast-enhanced CT for preoperative tumor staging of advanced gastric cancer, suggesting that transabdominal oral contrast-enhanced US is promising for future routine clinical diagnosis. It has diagnostic accuracy approximately equivalent to that of CT and is easily accepted by patients. Importantly, the instruments and techniques for transabdominal oral contrast-enhanced US are much more readily available than those for CT, and ionizing radiation is not used. Because of these advantages, transabdominal oral contrast-enhanced US can be used for diagnosing gastric cancer in developing areas.
There were no T1 cases in this study, so the performance of transabdominal oral contrast-enhanced US as an aid to T1 staging cannot be addressed here. Node and metastasis staging were not available from this study; however, we will investigate node staging using transabdominal oral contrast-enhanced US in future research. Moreover, the correlation between tumor staging accuracy and the anatomic tumor site cannot be addressed here. This study was also limited by the small sample size, and retrospective assessment of US images is always difficult 29 ; therefore, a prospective pilot study with a larger sample size is warranted.
In conclusion, transabdominal oral contrastenhanced US has substantial potential value in preoperative tumor staging of gastric cancer. It is noninvasive, cost-effective, and widely available and has accuracy comparable with that of CT for staging gastric cancer.
